SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is currently trending with strong community enthusiasm, driven by the launch of staking features that reinforce its "pure belief asset" narrative. Members are actively discussing the project as a revolutionary alternative to traditional retirement plans, symbolizing a movement to empower retail investors. This highly engaged community, often comparing itself to past market movements, emphasizes conviction and the goal of early financial freedom.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is currently experiencing heightened community discussion, driven by strong bullish sentiment and predictions for significant long-term growth. Investors are actively debating its enduring role as "digital silver" within the crypto ecosystem, with many anticipating substantial future gains based on historical market cycles.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amidst an intense community debate, largely driven by persistent rumors of major partnerships with Mastercard and Walmart that could significantly expand Flexa's real-world crypto payment utility. Despite widespread frustration over its past performance and perceived market manipulation, a dedicated investor base maintains that AMP's existing merchant adoption and underlying technology position it as severely undervalued, especially with impending regulatory clarity from the "Clarity Act." This sentiment reflects a critical balance between immediate market skepticism and long-term conviction in its payment infrastructure.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume following news of a strategic manufacturing partnership with Syrma Johari, aimed at scaling production of its fingerprint drug screening reader for anticipated U.S. market entry. This has sparked intense community discussion, with many anticipating significant gains and potential for a short squeeze given the stock's low float, while others express caution regarding a recent offering and potential dilution.

Piggy Bank Token

PIGGY CRYPTO is trending due to its unique real-world utility in Korea's phone charging market, employing a "Charge-to-Earn" model, alongside a recent "A-grade" CertiK security audit. The community is buzzing with bullish sentiment, highlighting strong developer efforts, impactful AMAs, and strategic community collaborations, including notable involvement from a former SafeMoon figure. This has fueled discussions around its growth potential and unique reflection-based tokenomics.

Fidelity Wise Origin Bitcoin Fund - Fidelity Wise Origin Bitcoin Fund Beneficial Interest

Fidelity Wise Origin Bitcoin Fund

Fidelity Wise Origin Bitcoin Fund (FBTC) is experiencing varied sentiment as recent ETF outflows spark community debate over Bitcoin's immediate direction. While some investors are actively adding to long-term positions, especially within retirement accounts, others point to volatility and market dynamics, questioning whether current price movements indicate consolidation or further pressure. This ongoing discussion highlights a split between confidence in institutional adoption and concerns about market manipulation.

Breaking Bread is a pioneer in Solana meme token designed around a simple and transparent rewards system. With 0% tax on trades, every holder benefits directly from activity without hidden costs or penalties. The token automatically redistributes 100% of creator rewards from Pump.fun back to the community, ensuring fair participation for all holders. The project emphasizes consistency, trust, and community engagement, framing daily “breaking of bread” rewards as both a symbolic ritual and a practical way to sustain value for those who participate.

Breaking Bread

BRBR (Breaking Bread) is captivating the crypto community as a pioneering Solana token offering passive $SOL rewards to holders with zero transaction taxes. Discussions revolve around its innovative 'first of its kind' model, strong community commitment, and consistent chart performance, driving enthusiasm for its long-term potential.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following pivotal FDA updates, notably the priority review acceptance for AXS-05 in Alzheimer's disease agitation and positive feedback supporting a submission for AXS-12 in narcolepsy. This has ignited strong bullish sentiment and a surge in trading activity, with the community enthusiastically discussing the company's expanding pipeline and its potential in central nervous system therapeutics.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending due to recent strategic moves, including pipeline expansion through acquisitions and manufacturing advancements for its lead anticoagulant candidate, Tecarfarin. The market is weighing the potential of these developments, including analyst-assigned price targets and FDA designations, against community concerns about cash burn, dilution, and the company's ability to fund pivotal Phase 3 trials. This creates a polarized discussion, highlighting the high-stakes nature of micro-cap biopharma investments.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The iShares Bitcoin ETF, IBIT, is a focal point of intense discussion, driven by a pending Bank of Japan rate decision that could influence Bitcoin's short-term price action, alongside a recent return of positive ETF inflows. Community sentiment is sharply divided between those anticipating a prolonged 'crypto winter' based on historical cycles and others highlighting sustained institutional accumulation and evolving market dynamics as key factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a clinical master supply agreement with Swiss healthcare company Roche (RHHBY) for hard-to-treat cancer therapies.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply">agreement</a> aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.Checkpoint inhibitors are a type of immunotherapy used to treat cancer. They work by blocking proteins called checkpoints that cancer cells use to evade the immune system.MAIA CEO Vlad Vitoc said that Ateganosine was found to be “highly synergistic and effective” in combination with Roche’s Atezolizumab in preclinical studies.MAIA’s Ateganosine is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.Ateganosine is presently being developed as a second or later line of treatment for NSCLC for patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.On Stocktwits, retail sentiment around MAIA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed unchanged at ‘low’ levels.<figure class="image"><img style="aspect-ratio:630/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_10_02_21_AM_png_d32286ea58.webp" alt="MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits" width="630" height="66"><figcaption>MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the new agreement.<stembedurl>https://stocktwits.com/MoneyHelix/message/618266998</stembedurl>Another opined that it's “not bad news.”<stembedurl>https://stocktwits.com/share97/message/618262353</stembedurl><a href="https://stocktwits.com/symbol/MAIA">MAIA stock </a>is down by 11% this year and by over 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/air-india-boeing-crash-emergency-power-system-may-have-deployed-mid-flight/chls3JTRR2d">Air India Boeing Crash: Report Says Emergency Power System May Have Deployed Mid-Flight, Raising Engine Failure Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Equity

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.


This account has been verified as an official MAIA representative.

Verified Account

MAIA Biotechnology

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

MAIA
MAIA Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAIA News

MAIAMAIA Biotechnology Inc